Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week Low – Here’s What Happened

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) hit a new 52-week low during trading on Friday . The stock traded as low as $20.75 and last traded at $20.75, with a volume of 18105 shares. The stock had previously closed at $21.50.

Analysts Set New Price Targets

Several brokerages have commented on KLRA. Leerink Partners began coverage on shares of Kailera Therapeutics in a report on Tuesday. They set an “outperform” rating and a $36.00 target price on the stock. William Blair began coverage on shares of Kailera Therapeutics in a report on Tuesday. They set an “outperform” rating on the stock. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a report on Wednesday. TD Cowen began coverage on shares of Kailera Therapeutics in a report on Tuesday. They set a “buy” rating and a $57.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Kailera Therapeutics in a report on Tuesday. They set an “overweight” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Kailera Therapeutics presently has an average rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Stock Down 2.6%

Insider Activity

In other Kailera Therapeutics news, Director Andrew T. Kaplan acquired 8,398,438 shares of the stock in a transaction dated Monday, April 20th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the acquisition, the director directly owned 26,255,581 shares of the company’s stock, valued at approximately $420,089,296. This trade represents a 47.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Rtw Investments, Lp acquired 500,000 shares of the stock in a transaction dated Monday, April 20th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the completion of the acquisition, the insider directly owned 10,776,820 shares of the company’s stock, valued at $172,429,120. The trade was a 4.87% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 10,460,938 shares of company stock worth $167,375,008 over the last ninety days.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.